Abstract
Umbilical cord blood represents an increasingly useful source of hematopoietic stem cells for Bone Marrow Transplantation (BMT), although currently, low cell numbers generally limit its use to pediatric patients. The aim of this study was to evaluate the routine use of a recently published volume reduction protocol for long term cord blood banking as was applied in a large number of cord blood samples. 950 cord blood samples with mean volume collected 78.81 ± 23.56 ml, Nucleated Cell (NC) 0.91 ± 0.44 × 109 NC, Monocytes (MN) 0.49 ± 0.23 × 109 MN and CD34+ HPCs (Haematopoietic Progenitors Stem Cells) 2.4 ± 2.08 × 106 CD34+ HPCs counts, have been collected respectively. We found a significant correlation between leukocyte counts and CD34+ HPCs with the volume collected (r=0.71, P<0.0001). We found a highly statistically significant correlation between leukocyte cell count and CD34+ HPCs cell number, (r=0.66, P<0.0001). After volume reduction the respective UCB units contained 1.06 ± 0.54 × 109 NC and 3.4 ± 3.07 × 106 CD34+ HPC , 17.88 ± 9.38 × 109 Red Blood Cells (RBC), while the viability and the volume were 92 ± 5.9 % and 6.43 ± 0.99 ml respectively.
Highlights
In haematopoietic reconstitution, Umbilical Cord Blood (UCB) is used as an alternative source of stem cells, especially in cases were matching of the major Human Leukocyte Antigen histocompatibility complex (HLA) for related or unrelated bone marrow or peripheral blood stem cell donor is not possible [1,2]
Ninety-five percent of the pregnant woman informed about donation agreed to the collection, while 5.3 percent were excluded due to microbial contamination (n=21) and positive serologic testing (n=4) or low volume and hematopoietic stem cell number (26)
The mean volume was 78.81 ± 23.56 ml corresponding to a Nucleated Cell (NC) 0.91 ± 0.44 × 109 and to 2.4 × 106 ± 2.08 × 106 CD34+ Haematopoetic Progenitors Stem Cells (HPCs) containing sufficient cells numbers for a pediatric transplantation
Summary
Umbilical Cord Blood (UCB) is used as an alternative source of stem cells, especially in cases were matching of the major Human Leukocyte Antigen histocompatibility complex (HLA) for related or unrelated bone marrow or peripheral blood stem cell donor is not possible [1,2]. Cord blood offers several advantages over bone marrow and peripheral blood as a source of stem cells. These advantages include the zero risk for the mother and infant during collection, the low frequency of transmitting infections like cytomegalovirus and the availability of immediate use. In addition since umbilical cord blood derived haematopoietic stem cells are more ‘naοve’ than proliferative cells from bone marrow, they seem to produce fewer complications associated with some aspects of HSC transplantation [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
